QuidelOrtho (NASDAQ:QDEL) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of QuidelOrtho (NASDAQ:QDEL) from a strong sell rating to a hold rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities research analysts have also recently commented on QDEL. UBS Group reaffirmed a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research note on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Jefferies Financial Group lowered QuidelOrtho from a “buy” rating to a “hold” rating and cut their price target for the stock from $35.00 to $12.50 in a report on Thursday, May 7th. Finally, Citigroup cut their price target on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, QuidelOrtho presently has an average rating of “Reduce” and a consensus price target of $14.88.

QuidelOrtho Trading Down 3.1%

NASDAQ QDEL opened at $14.12 on Monday. The business has a 50 day simple moving average of $12.91 and a 200 day simple moving average of $21.06. QuidelOrtho has a one year low of $9.92 and a one year high of $35.58. The stock has a market capitalization of $962.84 million, a P/E ratio of -0.79 and a beta of 0.77. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80.

QuidelOrtho (NASDAQ:QDEL) last released its earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same period in the prior year, the business earned $0.74 EPS. The company’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Research analysts expect that QuidelOrtho will post 1.83 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of QDEL. Global Retirement Partners LLC lifted its holdings in shares of QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after purchasing an additional 886 shares in the last quarter. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $29,000. Hantz Financial Services Inc. lifted its holdings in shares of QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after purchasing an additional 362 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares in the last quarter. Finally, Leonteq Securities AG increased its position in shares of QuidelOrtho by 555.2% during the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock valued at $57,000 after acquiring an additional 2,937 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.